Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 May;65(5):751–755. doi: 10.1038/bjc.1992.158

Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters.

P J Johnson 1, N Dobbs 1, C Kalayci 1, M C Aldous 1, P Harper 1, E M Metivier 1, R Williams 1
PMCID: PMC1977380  PMID: 1316777

Abstract

A standard dose of Adriamycin (60 mg m-2) was administered to 30 patients with inoperable hepatocellular carcinoma, 16 of whom were hyperbilirubinaemic (18-37 mumol l-1). The hyperbilirubinaemic patients experienced marked myelosuppression, but only minor symptomatic side-effects. The degree of neutropenia was directly related to the serum bilirubin concentration, but not to any other standard liver test, presence or absence of cirrhosis, or any pharmacokinetic parameter studied including the area under the Adriamycin or adriamycinol concentration-time curve to 48 h or infinity, or the terminal half-life of Adriamycin. The area under the log concentration-time curve was significantly greater for both Adriamycin and adriamycinol in patients who were hyperbilirubinaemic compared to those with normal bilirubin. Whilst hyperbilirubinaemic patients may tolerate a full dose of Adriamycin, we found no evidence that this was associated with a better response rate, which was disappointingly low at only 18%.

Full text

PDF
755

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Brenner D. E., Chou F. T., Kubo H., Bachur N. R. Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos. 1980 May-Jun;8(3):152–156. [PubMed] [Google Scholar]
  2. Ballet F., Barbare J. C., Poupon R. Hepatic extraction of adriamycin in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol. 1984 Jun;20(6):761–764. doi: 10.1016/0277-5379(84)90213-x. [DOI] [PubMed] [Google Scholar]
  3. Chan K. K., Chlebowski R. T., Tong M., Chen H. S., Gross J. F., Bateman J. R. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res. 1980 Apr;40(4):1263–1268. [PubMed] [Google Scholar]
  4. Chlebowski R. T., Chan K. K., Tong M. J., Weiner J. M., Ryden V. M., Bateman J. R. Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. Cancer. 1981 Sep 1;48(5):1088–1095. doi: 10.1002/1097-0142(19810901)48:5<1088::aid-cncr2820480507>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  5. Chlebowski R. T., Chan K. K., Tong M. J., Weiner J. M., Ryden V. M., Bateman J. R. Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. Cancer. 1981 Sep 1;48(5):1088–1095. doi: 10.1002/1097-0142(19810901)48:5<1088::aid-cncr2820480507>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  6. Garnick M. B., Ensminger W. D., Israel M. A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res. 1979 Oct;39(10):4105–4110. [PubMed] [Google Scholar]
  7. Johnson P. J., Alexopoulos A., Johnson R. D., Williams R. Significance of serum bilirubin level in response of hepatocellular carcinoma to doxorubicin. J Hepatol. 1986;3(2):149–153. doi: 10.1016/s0168-8278(86)80020-4. [DOI] [PubMed] [Google Scholar]
  8. Johnson P. J., Williams R., Thomas H., Sherlock S., Murray-Lyon I. M. Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet. 1978 May 13;1(8072):1006–1009. doi: 10.1016/s0140-6736(78)90735-3. [DOI] [PubMed] [Google Scholar]
  9. Johnston A., Woollard R. C. STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983 May;9(3):193–199. doi: 10.1016/0160-5402(83)90038-4. [DOI] [PubMed] [Google Scholar]
  10. Kaye S. B., Cummings J., Kerr D. J. How much does liver disease affect the pharmacokinetics of adriamycin? Eur J Cancer Clin Oncol. 1985 Aug;21(8):893–895. doi: 10.1016/0277-5379(85)90103-8. [DOI] [PubMed] [Google Scholar]
  11. Olweny C. L., Toya T., Katongole-Mbidde E., Mugerwa J., Kyalwazi S. K., Cohen H. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer. 1975 Oct;36(4):1250–1257. doi: 10.1002/1097-0142(197510)36:4<1250::aid-cncr2820360410>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  12. Vogel C. L., Bayley A. C., Brooker R. J., Anthony P. P., Ziegler J. L. A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer. 1977 May;39(5):1923–1929. doi: 10.1002/1097-0142(197705)39:5<1923::aid-cncr2820390502>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  13. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]
  14. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981 Nov;4(11):879–885. doi: 10.1248/bpb1978.4.879. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES